Advertisement

Table of Contents

Masters of Immunology

Cancer Immunology at the Crossroads: Public/Private Partnership

Milestones in Cancer Immunology

Cancer Immunology Miniatures

  • Cancer Immunology Miniatures
    An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non–Small Cell Lung Cancer
    Encouse B. Golden, Sandra Demaria, Peter B. Schiff, Abraham Chachoua and Silvia C. Formenti
    Cancer Immunol Res December 1 2013 1 (6) 365-372; DOI:10.1158/2326-6066.CIR-13-0115

    The combination of local radiotherapy to a liver metastasis and systemic anti-CTLA-4 antibody resulted in a sustained complete clinical and radiologic remission in a patient with chemotherapy-refractory metastatic non–small cell lung cancer.

  • Cancer Immunology Miniatures
    Severe Cutaneous and Neurologic Toxicity in Melanoma Patients during Vemurafenib Administration Following Anti-PD-1 Therapy
    Douglas B. Johnson, Erika K. Wallender, Daniel N. Cohen, Sunaina S. Likhari, Jeffrey P. Zwerner, Jennifer G. Powers, Lisa Shinn, Mark C. Kelley, Richard W. Joseph and Jeffrey A. Sosman
    Cancer Immunol Res December 1 2013 1 (6) 373-377; DOI:10.1158/2326-6066.CIR-13-0092

    Severe systemic toxicities developed in two patients during vemurafenib therapy following disease progression after treatment with anti-PD-1 agents; these results have important implications for the management of melanoma patients and future clinical trials involving anti-PD-1 and BRAF inhibitors.

Priority Briefs

  • Priority Briefs
    Inverse Association between Programmed Death Ligand 1 and Genes in the VEGF Pathway in Primary Clear Cell Renal Cell Carcinoma
    Richard W. Joseph, Mansi Parasramka, Jeanette E. Eckel-Passow, Dan Serie, Kevin Wu, Liuyan Jiang, Krishna Kalari, R. Houston Thompson, Thai Huu Ho, Erik P. Castle, John Cheville, Eugene D. Kwon, E. Aubrey Thompson and Alexander Parker
    Cancer Immunol Res December 1 2013 1 (6) 378-385; DOI:10.1158/2326-6066.CIR-13-0042

    In a retrospective, nested, case–control study of 98 primary clear cell renal cell carcinoma tumors, Joseph and colleagues demonstrate an inverse correlation between genes in the VEGF pathway and PD-L1 expression, providing further support of the immunosuppressive role of VEGF on the tumor microenvironment.

  • Priority Briefs
    mTOR Inhibition Improves Antitumor Effects of Vaccination with Antigen-Encoding RNA
    Mustafa Diken, Sebastian Kreiter, Fulvia Vascotto, Abderraouf Selmi, Sebastian Attig, Jan Diekmann, Christoph Huber, Özlem Türeci and Ugur Sahin
    Cancer Immunol Res December 1 2013 1 (6) 386-392; DOI:10.1158/2326-6066.CIR-13-0046

    Diken, Kreiter, and colleagues report that treatment of mice in the B16 melanoma model with rapamycin at the effector-to-memory transition phase skews the vaccine-induced immune response toward the memory pool, with alterations of the tumor microenvironment, and prolongs survival.

Research Articles

  • Research Articles
    CD8+ T-cell Responses Rapidly Select for Antigen-Negative Tumor Cells in the Prostate
    S. Peter Bak, Mike Stein Barnkob, K. Dane Wittrup and Jianzhu Chen
    Cancer Immunol Res December 1 2013 1 (6) 393-401; DOI:10.1158/2326-6066.CIR-13-0109

    Bak, Barnkob, and colleagues show that treatment with antigen-specific CD8+ T cells effectively eliminated antigen-expressing prostate cells within the tumor bed, but the antigen-negative tumor cells with downregulated MHC class I continued to grow.

  • Research Articles
    Plasmacytoid Dendritic Cells Support Melanoma Progression by Promoting Th2 and Regulatory Immunity through OX40L and ICOSL
    Caroline Aspord, Marie-Therese Leccia, Julie Charles and Joel Plumas
    Cancer Immunol Res December 1 2013 1 (6) 402-415; DOI:10.1158/2326-6066.CIR-13-0114-T

    Combining the analyses of samples from melanoma patients and from melanoma-bearing humanized mice, the authors delineated the mechanism by which plasmacytoid dendritic cells mediate tumor progression and early relapse and identified potential therapeutic options for patients with metastatic melanoma.

  • Research Articles
    Escalating Regulation of 5T4-Specific IFN-γ+ CD4+ T Cells Distinguishes Colorectal Cancer Patients from Healthy Controls and Provides a Target for In Vivo Therapy
    Martin Scurr, Anja Bloom, Tom Pembroke, Rohit Srinivasan, Clare Brown, Kathryn Smart, Hayley Bridgeman, Mike Davies, Rachel Hargest, Simon Phillips, Adam Christian, Tom Hockey, Awen Gallimore and Andrew Godkin
    Cancer Immunol Res December 1 2013 1 (6) 416-425; DOI:10.1158/2326-6066.CIR-13-0035

    Using overlapping peptides spanning oncofetal antigen 5T4 as targets, Scurr and colleagues identify an inverse correlation between the anti-5T4 CD4+ T-cell responses in peripheral blood and colorectal cancer disease progression and show this selective loss is driven in part by regulatory T cells.

  • Research Articles
    Novel Mechanism of Tumor Suppression by Polarity Gene Discs Large 1 (DLG1) Revealed in a Murine Model of Pediatric B-ALL
    Gabriel J. Sandoval, Daniel B. Graham, Grzegorz B. Gmyrek, Holly M. Akilesh, Keiko Fujikawa, Benedicte Sammut, Deepta Bhattacharya, Shuba Srivatsan, Alfred Kim, Andrey S. Shaw, Katherine Yang-Iott, Craig H. Bassing, Eric Duncavage, Ramnik J. Xavier and Wojciech Swat
    Cancer Immunol Res December 1 2013 1 (6) 426-437; DOI:10.1158/2326-6066.CIR-13-0065

    Using two different murine models of pre–B-cell leukemia, Sandoval and colleagues delineate the mechanism of tumor suppression by the PDZ domain polarity gene DLG1, which interacts with and stabilizes the PTEN protein in early-stage B cells.

Correction

Reviewers

Back to top
Cancer Immunology Research: 1 (6)
December 2013
Volume 1, Issue 6

Sign up for alerts

Jump to

Advertisement